US FDA clears first blood test for Alzheimer's detection
Bengaluru: The U.S. Food and Drug Administration has cleared
Fujirebio Diagnostics
' blood test to diagnose Alzheimer's disease, the regulator said on Friday, making the device the first of its kind to detect the brain-wasting condition.
Blood tests could speed up diagnosis of the disease and make it easier for more people to access its treatments such as Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, since traditional tests are often costly or uncomfortable.
Fujirebio's test, branded as Lumipulse, checks for two proteins in the blood and uses their ratio to help detect signs of amyloid beta plaque, considered a hallmark of the disease, in the brain.
Other options to detect Alzheimer's include procedures such as a spinal tap, which requires an invasive puncture to collect spinal fluid, or an expensive PET brain scan that may not be reimbursed by health insurers.
"Street expectations for both therapies (Leqembi and Kisunla) are modest" with a slow ramp over the next few years, given the lack of access to neurologists, said Citi analyst Geoffrey Meacham. "An approved blood-based diagnostic is a positive in a disease area that has been starved of game-changing innovation."
Biogen has been doubling down on Leqembi but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side effects.
In the first quarter, Leqembi brought $96 million in sales, while Lilly recorded $21.5 million in Kisunla sales.
Lumipulse and C2N Diagnostics' PrecivityAD2 were the top two performers when compared with four other commercial blood tests for Alzheimer's, according to a study led by researchers at Washington University School of Medicine.
Biogen has partnered with Fujirebio, and Eisai is collaborating with C2N to clinically advance and commercialize blood tests that can detect Alzheimer's risk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
19 hours ago
- Time of India
Finger movements may hold the secret to Alzheimer's diagnosis, new study reveals
A groundbreaking study has found a possible link between finger movement patterns and brain changes in patients suffering from Alzheimer's disease, which can give rise to a new non-invasive diagnostic method. The research, published in the Journal of Alzheimer's Disease, examines how subtle variations in finger movement, timing, rhythm, and coordination can be indicative of changes in the brain structure characteristic of dementia. This is an important issue given that Alzheimer's, the most common form of dementia, accounts for 60–80% of the total number of cases globally. Why are finger movements significant? The study was carried out by Junpei Sugioka and some neurologists and neuroscientists from Japan. They used a voxel-based analysis technique called VSRAD (Voxel-based Specific Regional Analysis System for Alzheimer's Disease) to compare brain atrophy patterns among patients with Alzheimer's disease. The software helps in detecting changes in a few regions of the brain, largely the medial temporal region, which is critical for cognition and memory. By correlating measures of finger movement with brain scans, the scientists discovered dramatic correlations between motor control dysfunction and brain volume loss in patients. That is, worsening fine motor skills—too commonly overlooked—may offer early biomarkers of neurodegeneration. Implications for early detection "Our results suggest that testing of motor function, and particularly finger movement analysis, could become a viable screening test for cognitive impairment," the authors wrote. This is especially significant in rural or low-resource settings, where access to expensive MRI scans and neurological tests might be limited. Finger-tapping tests, possibly integrated into mobile health software, could be scalable alternatives. Further, screening with such could be done as a regular checkup for older persons. The wider context Aging remains the biggest risk for dementia. As the world's population ages, early diagnostic technologies that are low-cost become increasingly important. Technologies like VSRAD and motor assessment with non-invasive devices may lead the way to community-level screening, allowing earlier treatment and improved outcomes for the patient. They recommend additional longitudinal and cross-validated research in various populations. If true, these results have the potential to transform clinicians' screening for Alzheimer's, redirecting attention away from memory tests alone and toward subtle physical signs that can be observed years before cognitive symptoms develop fully. Is this a more general problem? This study's findings reveal not just a new diagnostic pathway but also signal the possibility of a greater and underestimated issue: systemic neglect of motor function as an early indication of neurological decline. In practice, cognitive symptoms like confusion or memory impairment are traditionally always given first attention, with physical signs like decelerated finger movement or small coordination issues being generally demoted to insignificance or irrelevance. One step to a healthier you—join Times Health+ Yoga and feel the change
The Hindu
a day ago
- The Hindu
Not all cognitive decline is dementia and not all dementia is Alzheimer's stress clinicians this brain awareness month
The estimated dementia prevalence in India is 7.4% among adults aged 60 and older. This translates to about 8.8 million Indians currently living with dementia. The prevalence is projected to increase significantly in the coming years, with estimates suggesting a rise to 1.7 crore (17 million) by 2036. And it is also increasingly recognised in India as a condition far more complex than memory loss. Dementia represents a progressive decline in cognitive abilities, including language, executive functioning, behaviour, and the capacity to perform daily tasks. Alzheimer's disease remains the most well-known form of dementia, but it is only one of many. Indian clinicians are now focusing on comprehensive evaluations to identify reversible causes, clarifying diagnoses using advanced biomarkers, and staying informed about global advances in therapy -- all while staying grounded in clinical realities and patient context. Identifying reversible causes -- a health priority in dementia care According to Prabash Prabhakaran, director and senior consultant- neurology, SIMS Hospital, Chennai, dementia is often misunderstood as only memory loss, whereas one of the earliest signs could be executive dysfunction --such as a person forgetting how to prepare a familiar dish . He also emphasises the importance of looking for apraxia, which is the loss of learned motor skills, along with changes in gait and bladder control. A distinctive pattern like 'magnetic gait,' where a person shuffles slowly and cannot lift their feet properly, may offer clues pointing to specific subtypes such as Normal Pressure Hydrocephalus. Even in patients with clear signs of cognitive decline, Dr. Prabhakaran warns against over-reliance on imaging or biomarker tests in isolation, stressing that without a robust clinical picture, these tools can mislead more than help. One of the most critical steps in dementia care in India is to rule out reversible causes before settling on a diagnosis like Alzheimer's. This clinical vigilance ensures that treatable conditions are not missed. For instance, vitamin B12 deficiency is a common cause of cognitive issues, especially among vegetarians, and can be easily corrected with supplements. Hypothyroidism is another frequently overlooked condition that can mimic dementia and is reversible with thyroid hormone replacement. Dr. Prabhakaran shares that cases of Normal Pressure Hydrocephalus -- where dementia presents alongside gait instability and bladder dysfunction -- can sometimes be reversed almost miraculously by draining around 30 ml of cerebrospinal fluid. There are also rarer possibilities like autoimmune dementia, which constitutes about two to three percent of cases. In such instances, antibody testing for approximately 23 known markers is now available in India. Familial dementia and vasculitis-related cognitive disorders also fall into this category of conditions where early detection can dramatically change outcomes. As Dr. Prabhakaran puts it, 'Even if just one patient benefits from identifying a reversible cause, the clinical effort is worth it.' Clinical evaluations to rule out health risks Imaging continues to be a helpful tool, not for confirmation but for exclusion. MRI scans are used to rule out brain masses, hydrocephalus, and vascular insults. While certain patterns of brain atrophy, particularly in the temporal and parietal lobes, may suggest Alzheimer's disease, these findings are supportive rather than definitive. FDG-PET scans, which measure glucose metabolism, can reveal hypometabolism in specific brain regions, often correlating with suspected Alzheimer's pathology. However, PET scans are advised only when there is already a strong clinical suspicion -- they are not used as screening tools. A major advancement in recent years is the use of blood-based biomarkers that measure levels of tau protein and beta-amyloid -- proteins central to Alzheimer's disease pathology. These are available in India but remain expensive and are not part of routine diagnostics. Dr. Prabhakaran explains that these tests are best used in specific scenarios: when the clinical presentation is ambiguous, when there is mild cognitive impairment, or in cases of early-onset or rapidly progressing dementia. He cautions against using biomarkers indiscriminately, underscoring that their role should always be hypothesis-driven. Srividhya S, associate consultant, department of neurology, Rela Hospital, Chennai notes that biomarker changes can occur nearly 20 years before symptoms appear. She highlights the usefulness of these tests in ruling out Alzheimer's, pointing to their strong negative predictive value. A negative result can give both doctors and families confidence to pursue alternative explanations and care pathways. The role of cerebrospinal fluid (CSF) testing also deserves attention. U. Meenakshisundaram, director & senior consultant, neurology, MGM Healthcare, Chennai, notes that Indian labs now offer CSF analysis for beta-amyloid and phosphorylated tau at a cost of around ₹20,000–₹25,000. Although it requires a lumbar puncture and is thus more invasive, many patients and families opt for it if it provides diagnostic clarity. He also mentions that newer, less invasive serum-based tests for Alzheimer's biomarkers have recently been approved in the United States, though these are not yet available in India. Post-diagnosis medical care and management In terms of treatment, there is growing global excitement about novel therapies. Dr. Meenakshisundaram emphasis that two monoclonal antibodies -- lecanemab and aducanumab -- have been approved in the United States in recent months. These therapies target amyloid plaques and aim to slow disease progression. Though not yet available in India, their approval marks a turning point in how the medical community thinks about Alzheimer's care. Aditya Gupta, director, neurosurgery & cyberknife, Artemis Hospital, Gurugram, stresses that we are now in an era where the goal is not just to manage symptoms but to attempt to modify disease progression. He says that early diagnosis paired with these emerging therapies may finally allow patients and caregivers to move from despair to hope. However, across all experts, there is consensus on several guiding principles. First, dementia is not synonymous with Alzheimer's disease. Diagnosing someone with Alzheimer's prematurely, especially without ruling out other causes, risks missing treatable conditions. Second, investigations must be pragmatically chosen. Dr. Prabhakaran insists that tests should only be performed if their results will influence clinical management. There is no merit in subjecting patients to expensive tests that do not offer actionable insights. Third, biomarkers are tools -- not solutions. They should only be used when the clinical context supports their necessity. Finally, there is a strong push to empower caregivers with knowledge. Early, accurate diagnosis, even if it confirms an irreversible condition, helps families prepare and cope more effectively with behavioural changes and caregiving needs. Cautious hope Experts say that the outlook for dementia care in India is cautiously hopeful. Clinicians are well-informed and increasingly equipped with both traditional tools and cutting-edge diagnostics. Public awareness is growing, particularly among caregivers who seek clarity and early intervention. The next challenge lies in making diagnostics and future therapies more accessible and affordable. With global trials progressing and India's healthcare ecosystem adapting rapidly, dementia care may soon offer more definitive pathways for diagnosis, management, and even therapeutic intervention. Dr. Prabhakaran adds, 'We are on the cusp of a change. A decade from now, early detection may not just offer clarity -- but treatment.' For now, the focus must remain on early clinical evaluation, ruling out reversible causes, and empowering caregivers with the knowledge and resources they need to navigate this complex condition.
News18
a day ago
- News18
The MIND Diet Explained: A Look At How This Eating Plan Supports Cognitive Health
Published By : Trending Desk Last Updated: The MIND diet is a scientifically developed eating plan designed to support brain health and lower the risk of neurodegenerative diseases. In today's fast-paced world, maintaining cognitive health and brain function has become a concern for many. While ageing naturally affects the brain, your lifestyle choices and diet plans can pave the way for better cognitive health. Many healthcare organisations have launched programmes aimed at improving cognitive performance and reducing the risk of diseases like Alzheimer's and dementia. This is where the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) comes in – a scientifically developed eating plan designed specifically to support brain health and lower the risk of neurodegenerative diseases. It's not just about living longer, but living well with a clear and active mind. A 2024 study published in Neurology claims that the MIND diet can significantly reduce the risk of memory decline. But How Does The MIND Diet Actually Work? The MIND diet is a blend of two highly regarded diets – It was first developed in 2015 at Rush University Medical Centre by Dr Clare Morris and her team. The diet focuses on including unprocessed, nutrient-rich foods that support brain health. The core idea is to prioritise natural, plant-based items while limiting unhealthy fats and processed foods. Whole Grains: Eat oats, brown rice, or whole wheat bread, ideally three times a day, for steady energy and stable blood sugar levels. Nuts: Almonds, walnuts, and Brazil nuts are a source of healthy fats and vitamin E, which may protect against cognitive decline. Consume two or three times per week. Legumes: Eat Lentils, chickpeas, beans, and soy at least three times a week. Poultry and Fish: Consuming lean chicken and fatty fish like salmon or mackerel at least once a week can provide your body with the protein it needs. What Should Be Avoided On The MIND Diet? Red meat, full-fat cheese, fried food, processed snacks, fast food, and alcohol are discouraged, as they are linked to inflammation and cognitive decline. What Are The Benefits Of The MIND Diet? Lowers the risk of memory loss and cognitive decline, It may help prevent neurodegenerative diseases like Alzheimer's, Supports heart health and regulates blood pressure, Aids in weight management, and Reduces the risk of type 2 diabetes. Adopting the MIND diet isn't about strict rules or cutting out entire food groups. It's about making conscious, mindful choices that nourish the brain. By incorporating these simple dietary habits into your daily routine, you can protect your memory and support long-term brain function.
